# Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct06572813/  
OnCo record `nct06572813` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of sintilimab and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by First Affiliated Hospital of Zhejiang University, now recruiting.

## Summary

Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06572813 by First Affiliated Hospital of Zhejiang University, with a registry enrolment figure of 63 participants, started 2024-11-15 and due to reach its primary completion in 2026-09-01. Interventions recorded: Bortezomib Injection; Sintilimab; mFOLFIRINOX. Conditions listed: Pancreas Cancer. Primary outcome: Phase 1: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0; Phase 2: Objective reponse rate (ORR). Pancreatic eligibility wording from the registry: "* Pathologically (histologically or cytologically) confirmed pancreatic ductal adenocarcinoma (PDAC)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: CISPD-7
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06572813
- Phase: 1/2
- Setting: Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for First-line Treatment of Metastatic Pancreatic Cancer：An Exploratory Clinical Trial
- Sponsor: First Affiliated Hospital of Zhejiang University
- Enrolled: 63

## Sources

- ClinicalTrials.gov NCT06572813: https://clinicaltrials.gov/study/NCT06572813

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06572813.json